SCHEDULE 13G/A: BlackRock Discloses 7.2% Passive Stake in AngioDynamics Inc.
Ownership Disclosure
BlackRock, Inc. has filed an Amendment No. 8 to Schedule 13G, disclosing a 7.2% passive beneficial ownership stake in AngioDynamics Inc. as of March 31, 2025.
Summary
- BlackRock, Inc. filed an Amendment No. 8 to Schedule 13G regarding its ownership in AngioDynamics Inc.
- As of March 31, 2025, BlackRock, Inc. beneficially owns 2,918,422 shares of AngioDynamics Inc. common stock.
- This represents 7.2% of the total outstanding common shares of AngioDynamics Inc.
- BlackRock holds sole voting power over 2,868,268 shares and sole dispositive power over 2,918,422 shares.
- The filing indicates that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
- Several BlackRock subsidiaries, including BlackRock Advisors, LLC, BlackRock Asset Management Canada Limited, BlackRock Fund Advisors, BlackRock Institutional Trust Company, National Association, BlackRock Financial Management, Inc., and BlackRock Investment Management, LLC, are identified as entities that may beneficially own 5% or greater of the outstanding shares.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing (Schedule 13G Amendment) disclosing a passive ownership stake. It contains factual information without any positive or negative commentary, making its sentiment neutral.
Industry Context
This filing is a routine disclosure by a major institutional investor, BlackRock, regarding its passive ownership stake in AngioDynamics Inc., a company operating in the medical device sector. Such disclosures are common for large asset managers and do not typically indicate a strategic shift within the industry, but rather reflect portfolio allocation decisions.
Stakeholder Impact
- This filing primarily impacts shareholders by providing transparency on a significant institutional ownership stake. It indicates that a major asset manager, BlackRock, holds a substantial, passive position in AngioDynamics Inc., which can be viewed as a vote of confidence in the company's long-term prospects by a large institutional investor.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Date of previously revoked Power of Attorney. |
| 2025-01-21 | Effective date of the new Power of Attorney. |
| 2025-03-31 | Date of event which requires filing of this statement (reporting period end date). |
| 2025-04-17 | Date of filing of this Schedule 13G Amendment No. 8. |
Keywords
AngioDynamics Inc, BlackRock Inc, Schedule 13G, Common Stock, Beneficial Ownership, Institutional Investor, Medical Devices, Healthcare
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.